Amgen to present new data on Repatha at ESC Congress
Will present 11 abstracts at the conference in Rome on Aug. 27-31. Read More »
Florida teen survives brain-eating amoeba infection
Miltefosine was used to treat Naegleria fowleri infection; the teen is only the third survivor of primary amebic meningoencephalitis. Read More »
Takara releases new line of beta cells for research
Human iPSC-derived beta cells now available for drug screening and diabetes research. Read More »
CVS Health 10 year support of Easterseals benefits young children
Over the past decade, CVS Health has invested more than $1.5 million to Easterseals in early childhood services, which has ensured the best possible start in life for tens of thousands of young children. Read More »
Gaugler joins Spectra as president
Joins experienced management team; will oversee contract sales organization. Read More »
Raptor to present at ERS International Congress 2016
Raptor Pharmaceuticals Corp., a biopharmaceutical company focused on the development and commercialization of transformative treatments to treat rare diseases, has announced its participation in the European Respiratory Society (ERS) International Congress 2016. Read More »
Positive results announced in Phase II trial to treat common warts
Aclaris announces results of A-101 topical solution to treat the common wart. Read More »
Health Center Partners to receive $1.5 million from HHS
Health Center Partners, a group of community health centers in San Diego, Riverside and Imperial counties in California, recently announced that is has been named the recipient of $1.5 million from the U.S. Department of Health and Human Services (HHS). Read More »
Stanley Crooke recipient of E. B. Hershberg Award
Stanley Crooke, founder, CEO and chairman of Ionis Pharmaceuticals, has been named the recipient of the E. B. Hershberg Award by the American Chemical Society for significant discoveries in medicinally active substances. Read More »
Fexapotide placebo crossover study reveals lower incidence of surgery
Men who received placebo and subsequent treatment with fexapotide show lower surgery rates. Read More »
Drug restrictions cut costs without negative impact on patients: study
A majority of health care plans and programs with a drug exclusion policy have been successful, reducing costs and not negatively impacting patient care, concludes a new study published in The American Journal of Managed Care. Read More »
CVS Health Research Institute releases new study showing interventions based on patient populations can save costs
The CVS Health Research Institute this week released the findings of a new study showing that it is extremely cost-efficient to intervene in order to increase medication adherence in patients suffering from common chronic conditions. Read More »
FDA tentatively approves generic version of Suprep
Perrigo also confirms lawsuit over generic version of Mirvaso topical gel. Read More »
First patient in CytoDyn PRO 140 study reaches two years of complete virologic suppression
CytoDyn Inc., a company specializing in biotechnology that is dedicated to the development of new antibody therapies for the treatment of human immunodeficiency virus (HIV), recently announced that the first of 11 patients with HIV-1 in its Phase 2b extension study of PRO 140 has achieved two years of complete virologic suppression. Read More »
BioPharmX Phase IIa trial shows 90 percent reduction in acne
BPX-01 topical minocycline reduces P. acnes after four weeks without entering bloodstream. Read More »
Missouri ‘expert witness’ debate watched closely by health products, pharma industries
In the wake of a large jury verdict against Johnson & Johnson, the health products industry is closely watching a debate over expert witness standard legislation in Missouri. Read More »
Hemispherx Biopharma forms scientific advisory board
The board members will use their expertise to guide the company and advance its drug development programs. Read More »
Munster Radiology Group contracts with McKesson
MRG anticipates improvements in customer and patient billing process, regulatory compliance and claims management. Read More »
FDA grants tentative approval to Supernus sNDA for Trokendi XR
.jpg)
Supernus Pharmaceuticals Inc. recently reported that its Supplemental New Drug Application (sNDA) that requested an expansion to the label of Trokendi XR to include prophylaxis for migraine headaches in adults has been granted tentative approval by the U.S. Food and Drug Administration (FDA). Read More »
Juniper’s COL-1077 fails to achieve primary, secondary goals
Juniper Pharmaceuticals Inc. announced last week its Phase IIb clinical trial for COL-1077, which was recently completed, did not meet either its primary or secondary goals. Read More »
Alerts Sign-up